The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

Por Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan
Publicado no Blood (2015)

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

Por Weisberg, Stuart P., Hunter, Deborah, Huber, Reid, Lemieux, Jacob, Slaymaker, Sarah, Vaddi, Kris, Charo, Israel, Leibel, Rudolph L., Ferrante, Anthony W.
Publicado em 2006

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

Por Weisberg, Stuart P., Hunter, Deborah, Huber, Reid, Lemieux, Jacob, Slaymaker, Sarah, Vaddi, Kris, Charo, Israel, Leibel, Rudolph L., Ferrante, Anthony W.
Publicado em 2006

Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples

Por Collier, Paul, Patel, Keyur, Waeltz, Paul, Rupar, Mark, Luthra, Rajyalakshmi, Liu, Phillip C.C., Hollis, Gregory, Huber, Reid, Verstovsek, Srdan, Burn, Timothy C.
Publicado no Genet Test Mol Biomarkers (2013)

DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1

Por Huber, Reid, Hansen, R. Scott, Strazzullo, Maria, Pengue, Gina, Mazzarella, Richard, D’Urso, Michele, Schlessinger, David, Pilia, Giuseppe, Gartler, Stanley M., D’Esposito, Maurizio
Publicado em 1999

The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

Por Rosenstock, Julio, Banarer, Salomon, Fonseca, Vivian A., Inzucchi, Silvio E., Sun, William, Yao, Wenqing, Hollis, Gregory, Flores, Robert, Levy, Richard, Williams, William V., Seckl, Jonathan R., Huber, Reid
Publicado em 2010

Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents

Por Wang, Liang-Chuan S, Koblish, Holly, Hansbury, Michael, Zhang, Yue, Yang, Gengjie, Burn, Timothy, Waeltz, Paul, Rupar, Mark, Yue, Eddy, Douty, Brent, Maduskuie, Thomas, Falahatpisheh, Nikoo, Li, Yun-Long, Combs, Andrew P, Hollis, Gregory, Huber, Reid, Scherle, Peggy
Publicado no J Immunother Cancer (2015)

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies

Por Koblish, Holly, Li, Yun-long, Shin, Niu, Hall, Leslie, Wang, Qian, Wang, Kathy, Covington, Maryanne, Marando, Cindy, Bowman, Kevin, Boer, Jason, Burke, Krista, Wynn, Richard, Margulis, Alex, Reuther, Gary W., Lambert, Que T., Dostalik Roman, Valerie, Zhang, Ke, Feng, Hao, Xue, Chu-Biao, Diamond, Sharon, Hollis, Greg, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Vaddi, Kris, Scherle, Peggy
Publicado no PLoS One (2018)

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Por Liu, Phillip C. C., Koblish, Holly, Wu, Liangxing, Bowman, Kevin, Diamond, Sharon, DiMatteo, Darlise, Zhang, Yue, Hansbury, Michael, Rupar, Mark, Wen, Xiaoming, Collier, Paul, Feldman, Patricia, Klabe, Ronald, Burke, Krista A., Soloviev, Maxim, Gardiner, Christine, He, Xin, Volgina, Alla, Covington, Maryanne, Ruggeri, Bruce, Wynn, Richard, Burn, Timothy C., Scherle, Peggy, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Hollis, Gregory
Publicado no PLoS One (2020)